Data Supporting SeptiCyte® RAPID Performance for COVID-19 Patient Triage Presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) by Immunexpress Collaborator

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced data presented by Immunexpress collaborator from a study supporting SeptiCyte® RAPID performance for COVID-19 patient triage at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) hybrid event, taking place online and in Lisbon, Portugal from April 23-26, 2022. SeptiCyte®…

Read More

Immunexpress CEO To Present at the Virtual Biotech Showcase 2022

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on-demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022.   Dr. Carlson will present an overview of Immunexpress’ SeptiCyte®…

Read More

FDA Clears SeptiCyte® RAPID – The First One-Hour, Direct-from-Blood Sepsis Test

Immunexpress.com

Fully automated diagnostic tool SeptiCyte® RAPID quantifies the relative expression levels of genes involved in a patient’s immune response to infection to aid in a diagnosis in one hour for patients suspected of sepsis Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has received…

Read More

Superior Sepsis Diagnostic Performance of SeptiCyte® RAPID Compared to Lactate and Procalcitonin Presented at IDWeek 2021

Immunexpress.com

SeptiCyte® RAPID proved superior to routinely used diagnostic tools for the differentiation of sepsis from infection negative systemic inflammation SEATTLE, Sept. 29, 2021 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation, titled “Comparison of lactate, procalcitonin and a gene signature assay alone or in combination to…

Read More

Immunexpress to Present SeptiCyte® RAPID Comparative Data Against Lactate and Procalcitonin for Diagnosing Sepsis at IDWeek 2021

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation demonstrating comparative data of SeptiCyte® RAPID, lactate, and procalcitonin in differentiating sepsis from infection negative systemic inflammation at IDWeek 2021, taking place virtually on Sept. 29 – Oct. 3, 2021.   Details of the presentations are as…

Read More

Immunexpress Announces SeptiCyte® RAPID Testing For Paediatric Sepsis

Immunexpress.com

BRISBANE, Australia, Aug. 24, 2021 /PRNewswire/ — Immunexpress, Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will be evaluated in the diagnosis of paediatric sepsis in Queensland children. The testing is in part funded through a Federal Government’s Medical Research Future Fund Genomic Health Futures Mission grant for collaborative work between The University of…

Read More

Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021

Immunexpress.com

SEATTLE, July 9, 2021 – Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a late-breaking presentation, titled “Use of SeptiCyte RAPID to assess the risk of ICU admission in COVID-19 patients” (ID#4984), demonstrating the performance of SeptiCyte® RAPID in triaging COVID-19 patients at the 31st European Congress…

Read More

Immunexpress Presents Data Further Demonstrating SeptiCyte® RAPID Performance at the Society of Critical Care Medicine’s 50th Annual Critical Care Congress

Immunexpress.com

Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis or systemic…

Read More

Immunexpress to Present SeptiCyte® RAPID Performance Data at the 50th Critical Care Congress

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine’s (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb. 12, 2021. The presentation highlights…

Read More

Immunexpress to Present SeptiCyte® RAPID Data at the Association for Molecular Pathology Annual Meeting

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data demonstrating performance, reproducibility and identification of fungal infections, in two poster presentations at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo on Nov. 16-20.   “Our SeptiCyte® technology leverages host-response gene-expression biomarkers…

Read More